<DOC>
	<DOCNO>NCT00002368</DOCNO>
	<brief_summary>To evaluate tolerance , safety , effectiveness Viramune prevent clinical AIDS progression event death use combination Lamivudine background nucleoside therapy .</brief_summary>
	<brief_title>The Safety Effectiveness Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs</brief_title>
	<detailed_description>Eligible patient randomize treatment either 1 ) open-label 3TC twice daily plus Viramune daily 2 week Viramune twice daily ; 2 ) open label 3TC twice daily plus Viramune placebo daily 2 week twice daily Viramune . Patients start Viramune 3TC study day 0 . Patients evaluate development AIDS progression event month 1 , 2 , 3 , 4 , every 2 month thereafter 18 month last patient enrol 24 month , whichever occur first .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV infection . CD4+ cell count &lt; = 200 cells/mm3 . Life expectancy &gt; 3 month . Written inform consent parent guardian patient &lt; 18 year age . Willingness ability follow protocol requirement . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Patient enrol plan enroll course study another clinical study antiretroviral agent use treat HIV1 infection . NOTE : Patients allow participate opportunistic infection clinical study investigational agent contraindicate study . Concurrent Medication : Excluded : Patient receive therapy antiretroviral agent ZDV , d4T , ddI , ddC , 3TC . Patient receive acute therapy clinical AIDS progression event systemic chemotherapy . Dicumarol , Warfarin anticoagulant medication . Tolbutamide . Investigational drug ( unless include opportunistic infection clinical trial ) antiretroviral agent ( exclude ZDV , ddC , ddI , d4T 3TC ) . Neurotoxic drug . Cimetidine . Erythromycin . Concurrent Treatment : Excluded : Radiation therapy . Patients follow prior condition symptom exclude : History clinically important disease HIV1 infection relate disease , opinion investigator , may put patient risk participation study . Prior Medication : Excluded : Patient receive prior therapy Viramune nonnucleoside reverse transcriptase inhibitor . Patient receive immunosuppressive cytotoxic drug experimental agent within 4 week prior study day 1 . Patient receive treatment erythromycin , coumadin/warfarin , phenobarbital , amoxicillin/clavulanic acid , ticarcillin/clavulanic acid within 2 week prior study day 0 . Risk Behavior : Excluded : Patients active chronic alcohol substance abuser active psychiatric condition sufficient impair compliance protocol requirement . Required : Patient must receive stable nucleoside therapy least one agent &gt; = 4 week prior study day 0 . Zidovudine ( ZDV ) , Zidovudine + Dideoxycytidine ( ddC ) , Zidovudine + Didanosine ( ddI ) must use unless prior intolerance precludes ZDV use . Stable use mean change dose &gt; 50 % background nucleoside within four week prior study day 0 . NOTE : If patient ZDV intolerant , ddC , ddI D4T monotherapy allow .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2002</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Disease Progression</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>